Scientists have uncovered a complex interplay between liver X and thyroid hormone receptors, offering new therapeutic possibilities for neurodegenerative disorders.
In a comprehensive researchers have unveiled fresh insights into how two types of hormone receptors collaborate to maintain brain health and potentially prevent neurodegenerative diseases.
The study, led by the University of Houston and Karolinska Institutet, demonstrates that liver X receptors (LXRs) and thyroid hormone receptors (TRs) work together in a previously unrecognised manner to regulate critical brain functions and protect against neurodegeneration.
Professor Margaret Warner, one of the study’s lead authors, says: “Our analysis reveals that LXRs and TRs don’t represent parallel pathways but rather constitute a single pathway through which the thyroid hormone endocrine system regulates cholesterol homeostasis.
“This discovery could fundamentally change how we approach treatment for various neurodegenerative conditions.”
Key findings include that LXRs play a crucial role in regulating thyroid hormone function in the brain and that both receptors are essential for normal brain development and maintenance.
Also, loss of LXR function leads to age-related neurodegeneration in multiple brain regions; while the receptors work together to maintain cholesterol balance in the brain.
The review highlights several promising therapeutic implications
In Alzheimer’s disease, LXR activation could help reduce amyloid plaque formation and improve memory, it says.
In relation to Parkinson’s, meanwhile, LXR signaling appears to protect dopamine-producing neurons.
LXRs can also influence motor neuron survival and function in ALS. The receptors also play crucial roles in myelin repair and maintenance in MS.
Co author Dr. Xiaoyu Song says: “What’s particularly intriguing is the age-dependent nature of these protective effects. Understanding why certain neurons become vulnerable to degeneration as we age could be key to developing preventive treatments.”
The research raises several compelling questions for future investigation.
How might targeting both receptor systems simultaneously enhance therapeutic outcomes? Could early intervention through these pathways prevent or delay the onset of neurodegenerative diseases? What role do different receptor variants play in different brain regions?
The review was published in the journal, Genomic Psychiatry.